Scinovex
article Open AccessTop 1% cited

Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke

New England Journal of Medicine · 2008 · Vol. 359(13) · pp. 1317–1329
Werner HackeMarkku KasteErich BluhmkiM BrozmanAntoni DávalosDonata GuidettiVincent LarrueKennedy R. LeesZakaria MedeghriThomas MachnigDietmar SchneiderRüdiger von KummerNils WahlgrenDanilo Toni

Abstract

As compared with placebo, intravenous alteplase administered between 3 and 4.5 hours after the onset of symptoms significantly improved clinical outcomes in patients with acute ischemic stroke; alteplase was more frequently associated with symptomatic intracranial hemorrhage. (ClinicalTrials.gov number, NCT00153036.)

Acute Ischemic Stroke ManagementStroke Rehabilitation and RecoveryCerebrovascular and Carotid Artery DiseasesMedicineThrombolysisStroke (engine)Ischemic strokeAcute strokeFibrinolytic agentTissue plasminogen activatorEmergency medicineAnesthesiaInternal medicine

MeSH terms

Acute DiseaseAdultAgedBrain IschemiaDouble-Blind MethodDrug Administration ScheduleFemaleFibrinolytic AgentsHumansInfusions, IntravenousMaleMiddle AgedTissue Plasminogen ActivatorTime FactorsLogistic Models

Funding

  • Bristol-Myers Squibb
  • Pfizer
  • Sanofi
  • Les Laboratories Pierre Fabre
  • Novo Nordisk
  • H. Lundbeck A/S
Citations
6,559
FWCI
203.99
field-weighted impact
References
23
Percentile
100%
vs. same field & year
Citations per year
References
Tissue Plasminogen Activator for Acute Ischemic Stroke
New England Journal of Medicine · 1995 · 11,620 citations
Functional evaluation : Barthel index
Medical Entomology and Zoology · 1965 · 12,854 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.